AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32779459 — intervention group
Group type: EXPERIMENTAL
Intervention: PF tafluprost/timolol FC
Number of subjects: 87
Study 35770524 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-set, high-load resistance exercise in hypoxia (inspiratory oxygen fraction = 0.145)
Number of subjects: 8
Study 35770524 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-set, high-load resistance exercise in hypoxia
Number of subjects: 8
Study 35770524 — intervention group
Group type: COMPARATOR
Intervention: Multi-set, high-load resistance exercise in hypoxia and normoxia
Number of subjects: 8
Study 35770524 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal isometric bench press trials after a 10-min hypoxic priming period
Number of subjects: 8
Study 33586513 — intervention group
Group type: EXPERIMENTAL
Intervention: G + chemo
Number of subjects: 0
Study 33586513 — intervention group
Group type: COMPARATOR
Intervention: Ra + chemo
Number of subjects: 0
Study 33586513 — intervention group
Group type: COMPARATOR
Intervention: Rp + chemo
Number of subjects: 0
Study 35015065 — intervention group
Group type: EXPERIMENTAL
Intervention: Written Exposure Therapy (5 weekly sessions)
Number of subjects: 169
Study 35015065 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Processing Therapy (12 twice-weekly sessions)
Number of subjects: 169
Study 33250456 — intervention group
Group type: EXPERIMENTAL
Intervention: Ergonomic workstation intervention
Number of subjects: 0
Study 33250456 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 0
Study 35900305 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractional CO2 laser
Number of subjects: 20
Study 35900305 — intervention group
Group type: COMPARATOR
Intervention: Fractional microneedle radiofrequency (FMR)
Number of subjects: 20
Study 34630934 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged Exposure (PE; 16 sessions in 16 weeks)
Number of subjects: 149
Study 34630934 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified Prolonged Exposure (iPE; 12 sessions in 4 weeks followed by 2 booster sessions)
Number of subjects: 149
Study 34630934 — intervention group
Group type: EXPERIMENTAL
Intervention: STAIR+Prolonged Exposure (STAIR+PE; 8 sessions of STAIR followed by 8 sessions of PE)
Number of subjects: 149
Study 34505829 — intervention group
Group type: COMPARATOR
Intervention: Placebo control in surgical trials
Number of subjects: 0
Study 34505829 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical interventions
Number of subjects: 0
Study 34505829 — intervention group
Group type: EXPERIMENTAL
Intervention: ASPIRE guidelines
Number of subjects: 0
Study 32552627 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotational thromboelastometry assays in patients with primary sclerosing cholangitis
Number of subjects: 80
Study 32552627 — intervention group
Group type: COMPARATOR
Intervention: Rotational thromboelastometry assays in patients with nonbiliary causes of cirrhosis
Number of subjects: 80
Study 32552627 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrinsic assay in patients with primary sclerosing cholangitis
Number of subjects: 80
Study 32552627 — intervention group
Group type: COMPARATOR
Intervention: Intrinsic assay in patients with nonbiliary causes of cirrhosis
Number of subjects: 80
Study 32552627 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall coagulation indexes in patients with primary sclerosing cholangitis
Number of subjects: 80
Study 32552627 — intervention group
Group type: COMPARATOR
Intervention: Overall coagulation indexes in patients with nonbiliary causes of cirrhosis
Number of subjects: 80
Study 35604680 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 0
Study 35604680 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 33687375 — intervention group
Group type: EXPERIMENTAL
Intervention: Home telemonitoring (TM)
Number of subjects: 201
Study 33687375 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 201
Study 32016500 — intervention group
Group type: COMPARATOR
Intervention: Conventional hump resection technique (Group A)
Number of subjects: 6
Study 32016500 — intervention group
Group type: EXPERIMENTAL
Intervention: Push-down procedure (Group B)
Number of subjects: 6
Study 32016500 — intervention group
Group type: EXPERIMENTAL
Intervention: Let-down procedure (Group C)
Number of subjects: 6
Study 35575603 — intervention group
Group type: EXPERIMENTAL
Intervention: The Connection Project (experiential, relationship‐focused intervention)
Number of subjects: 438
Study 35575603 — intervention group
Group type: COMPARATOR
Intervention: Waitlist-control
Number of subjects: 438
Study 33694072 — intervention group
Group type: EXPERIMENTAL
Intervention: Coordinated case management across medical, mental health, and social service organizations (n = 486)
Number of subjects: 895
Study 33694072 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n = 409)
Number of subjects: 895
Study 35180287 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive exercise intervention (two daily sessions of moderate-intensity exercises)
Number of subjects: 323
Study 35180287 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 323
Study 35180287 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive exercise intervention
Number of subjects: 323
Study 34164887 — intervention group
Group type: EXPERIMENTAL
Intervention: Ato‐Oxy plus zolpidem (10 mg)
Number of subjects: 12
Study 34164887 — intervention group
Group type: COMPARATOR
Intervention: Ato‐Oxy plus placebo
Number of subjects: 12
Study 32709645 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritionally modified infant formula
Number of subjects: 1923
Study 32709645 — intervention group
Group type: COMPARATOR
Intervention: Standard formula
Number of subjects: 1923
Study 36251422 — intervention group
Group type: EXPERIMENTAL
Intervention: Renin-Angiotensin System Inhibitors (RASi)
Number of subjects: 7174
Study 36251422 — intervention group
Group type: COMPARATOR
Intervention: Calcium channel blocker or thiazide diuretic (control)
Number of subjects: 7174
Study 35763114 — intervention group
Group type: EXPERIMENTAL
Intervention: Amifampridine
Number of subjects: 13
Study 35763114 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 34560015 — intervention group
Group type: EXPERIMENTAL
Intervention: PXL770 250 mg once daily
Number of subjects: 120
Study 34560015 — intervention group
Group type: EXPERIMENTAL
Intervention: PXL770 250 mg twice daily
Number of subjects: 120
Study 34560015 — intervention group
Group type: EXPERIMENTAL
Intervention: PXL770 500 mg once daily
Number of subjects: 120
Study 34560015 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 34560015 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 120
Study 32863275 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic hysterectomy
Number of subjects: 50
Study 32863275 — intervention group
Group type: COMPARATOR
Intervention: Abdominal hysterectomy
Number of subjects: 50
Study 36314868 — intervention group
Group type: EXPERIMENTAL
Intervention: LHF-535 (0.3 mg/kg to 40 mg/kg single ascending dose)
Number of subjects: 16
Study 36314868 — intervention group
Group type: EXPERIMENTAL
Intervention: LHF-535 (450 mg/day, 900 mg/day, 1,125 mg/day for 14 days, with a loading dose of 2,250 mg for the first dose in the 1,125 mg/day cohort)
Number of subjects: 16
Study 36314868 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 34102807 — intervention group
Group type: EXPERIMENTAL
Intervention: HMS Plus
Number of subjects: 188
Study 34102807 — intervention group
Group type: COMPARATOR
Intervention: ACT Plus
Number of subjects: 188
Study 32366280 — intervention group
Group type: EXPERIMENTAL
Intervention: Belimumab 10 mg/kg
Number of subjects: 554
Study 32366280 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 554
Study 36031789 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolutegravir-based therapy
Number of subjects: 464
Study 35130224 — intervention group
Group type: EXPERIMENTAL
Intervention: Aescin
Number of subjects: 360
Study 35130224 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone
Number of subjects: 360
Study 35130224 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 360
Study 35536489 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity training with Bryndza cheese
Number of subjects: 24
Study 35536489 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity training without Bryndza cheese
Number of subjects: 24
Study 32650771 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital integrated healthcare platform with continuous glucose monitoring and feedback from medical staff (Experimental group C)
Number of subjects: 0
Study 32650771 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital integrated healthcare platform by themselves without feedback (Experimental group B)
Number of subjects: 0
Study 32650771 — intervention group
Group type: COMPARATOR
Intervention: Routine diabetes care (Control group A)
Number of subjects: 0
Study 34074945 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy (CT)
Number of subjects: 521
Study 34074945 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR)
Number of subjects: 521
Study 34074945 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavior therapy (BT)
Number of subjects: 521
Study 34074945 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 521
Study 33920232 — intervention group
Group type: EXPERIMENTAL
Intervention: AREDS formulation with added DHA, lutein, zeaxanthin, resveratrol, and hydroxytyrosol (intervention group)
Number of subjects: 109
Study 33920232 — intervention group
Group type: COMPARATOR
Intervention: AREDS formulation (control group)
Number of subjects: 109
Study 33020152 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (DP)
Number of subjects: 580
Study 33020152 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfadoxine-pyrimethamine (SP)
Number of subjects: 580
Study 36273651 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA) 100mg, 2ml
Number of subjects: 130
Study 36273651 — intervention group
Group type: COMPARATOR
Intervention: Adrenaline 0.2mg, 2ml (1:10000)
Number of subjects: 130
Study 36273651 — intervention group
Group type: EXPERIMENTAL
Intervention: Both TXA and adrenaline
Number of subjects: 130
Study 33223487 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintedanib
Number of subjects: 288
Study 33223487 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 288
Study 33846152 — intervention group
Group type: EXPERIMENTAL
Intervention: Core outcome set defined through a Delphi process involving surgical and non-surgical stakeholders
Number of subjects: 0
Study 34601160 — intervention group
Group type: EXPERIMENTAL
Intervention: TXA plus topical CSS
Number of subjects: 150
Study 34601160 — intervention group
Group type: COMPARATOR
Intervention: TXA only
Number of subjects: 150
Study 34601160 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 33823461 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline WMHv (1.62 mL median, IQR 0.66–3.98 mL)
Number of subjects: 717
Study 33823461 — intervention group
Group type: EXPERIMENTAL
Intervention: Log-transformed WMHv
Number of subjects: 717
Study 33823461 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest quartile of WMHv
Number of subjects: 717
Study 32742143 — intervention group
Group type: EXPERIMENTAL
Intervention: Group cessation intervention plus pharmacotherapy
Number of subjects: 347
Study 34036434 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5% HX‐BGC
Number of subjects: 195
Study 34036434 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% sodium fluoride (NaF)
Number of subjects: 195
Study 34036434 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 195
Study 35081762 — intervention group
Group type: EXPERIMENTAL
Intervention: GE + TN
Number of subjects: 504
Study 35081762 — intervention group
Group type: COMPARATOR
Intervention: GE
Number of subjects: 504
Study 34676656 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold atmospheric plasma (CAP) applied twice a week for six consecutive weeks in addition to standard wound care
Number of subjects: 20
Study 34676656 — intervention group
Group type: COMPARATOR
Intervention: Standard wound care
Number of subjects: 20
Study 32450497 — intervention group
Group type: EXPERIMENTAL
Intervention: brexpiprazole 2 or 4 mg/day
Number of subjects: 38
Study 35449322 — intervention group
Group type: EXPERIMENTAL
Intervention: Citrate-free formulation of ixekizumab (1 mL SC injection)
Number of subjects: 315
Study 35449322 — intervention group
Group type: COMPARATOR
Intervention: Commercial formulation of ixekizumab (1 mL SC injection)
Number of subjects: 315
Study 35449322 — intervention group
Group type: EXPERIMENTAL
Intervention: Citrate-free formulation of ixekizumab (80 mg single SC injection)
Number of subjects: 315
Study 35449322 — intervention group
Group type: COMPARATOR
Intervention: Commercial formulation of ixekizumab (80 mg single SC injection)
Number of subjects: 315
Study 32396902 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-sampled specimens
Number of subjects: 300
Study 32396902 — intervention group
Group type: COMPARATOR
Intervention: Physician-sampled specimens
Number of subjects: 300
Study 36463592 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational program for clinical educators (e-learning and seminar)
Number of subjects: 77
Study 36463592 — intervention group
Group type: COMPARATOR
Intervention: Control group (no educational intervention)
Number of subjects: 77
Study 32875421 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical drains
Number of subjects: 584
Study 32875421 — intervention group
Group type: COMPARATOR
Intervention: No surgical drains
Number of subjects: 584
Study 32875421 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged drain removal (after postoperative day 13)
Number of subjects: 584
Study 32134309 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandatory behavioral staff-training program consisting of didactic training followed by a written exam, and in vivo training and assessment.
Number of subjects: 0
Study 32134309 — intervention group
Group type: EXPERIMENTAL
Intervention: Completion of the staff-training program.
Number of subjects: 0
Study 32134309 — intervention group
Group type: EXPERIMENTAL
Intervention: Written and in vivo test scores from staff training.
Number of subjects: 0
Study 32134309 — intervention group
Group type: EXPERIMENTAL
Intervention: Staff who disagreed with behavioral management principles.
Number of subjects: 0
Study 36192924 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese Medical Nutrition Therapy (CMNT) diet for T2D patients (5-day low-calorie diet followed by 10 days of habitual eating for 90 days)
Number of subjects: 39
Study 36192924 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese Medical Nutrition Therapy (CMNT) diet for db/db mice (low-calorie mouse CMNT diet in day 1-4 and ad libitum regular chow for up to 7 days per cycle)
Number of subjects: 39
Study 36192924 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal diet for T2D patients)
Number of subjects: 39
Study 36192924 — intervention group
Group type: COMPARATOR
Intervention: Control group (ad libitum access to regular chow for db/db mice)
Number of subjects: 39
Study 33721740 — intervention group
Group type: EXPERIMENTAL
Intervention: Harry Potter-based mental health literacy curriculum (3-month teacher-delivered intervention)
Number of subjects: 200
Study 32293383 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive Behaviour Support (PBS) delivered by health professionals
Number of subjects: 113
Study 32293383 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 113
Study 32293383 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive Behaviour Support (PBS)
Number of subjects: 113
Study 34074963 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuman Systems Model intervention
Number of subjects: 70
Study 34074963 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 70
Study 35595804 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent pneumatic compression (IPC)
Number of subjects: 275
Study 35595804 — intervention group
Group type: COMPARATOR
Intervention: Control (pharmacologic thromboprophylaxis alone)
Number of subjects: 275
Study 33302675 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal ultrasound (including two-dimensional ultrasound, Doppler ultrasound, contrast-enhanced ultrasound (CEUS), elastography)
Number of subjects: 0
Study 33302675 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal ultrasound
Number of subjects: 0
Study 33302675 — intervention group
Group type: EXPERIMENTAL
Intervention: CEUS and elastography
Number of subjects: 0
Study 33302675 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound and CT
Number of subjects: 0
Study 33302675 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound
Number of subjects: 0
Study 35370814 — intervention group
Group type: EXPERIMENTAL
Intervention: S‐AII (self-affirming implementation intention)
Number of subjects: 222
Study 35370814 — intervention group
Group type: EXPERIMENTAL
Intervention: BS‐AII (body-related self-affirming implementation intention)
Number of subjects: 222
Study 35370814 — intervention group
Group type: COMPARATOR
Intervention: MGI (mere goal intention—control condition)
Number of subjects: 222
Study 35370814 — intervention group
Group type: EXPERIMENTAL
Intervention: S‐AII + B (booster)
Number of subjects: 222
Study 35370814 — intervention group
Group type: EXPERIMENTAL
Intervention: BS‐AII + B (booster)
Number of subjects: 222
Study 35370814 — intervention group
Group type: COMPARATOR
Intervention: MGI + B (booster)
Number of subjects: 222
Study 33320098 — intervention group
Group type: EXPERIMENTAL
Intervention: mEMR usage (frequent users defined as logging in more than once a day)
Number of subjects: 87
Study 33320098 — intervention group
Group type: EXPERIMENTAL
Intervention: mEMR usage (frequent users)
Number of subjects: 87
Study 36398423 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine/remifentanil and low dose sevoflurane anaesthesia
Number of subjects: 32
Study 36398423 — intervention group
Group type: COMPARATOR
Intervention: Standard sevoflurane anaesthesia
Number of subjects: 32
Study 33792111 — intervention group
Group type: EXPERIMENTAL
Intervention: Sea buckthorn cream
Number of subjects: 55
Study 33792111 — intervention group
Group type: COMPARATOR
Intervention: 1% silver sulfadiazine (SSD)
Number of subjects: 55
Study 32194195 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter mitral valve repair (TMVr) with the MitraClip
Number of subjects: 551
Study 32194195 — intervention group
Group type: COMPARATOR
Intervention: Guideline-directed medical therapy (GDMT) alone
Number of subjects: 551
Study 32194195 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in KCCQ-OS (continuous variable)
Number of subjects: 551
Study 32194195 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in KCCQ-OS (after adjusting for demographic and clinical factors)
Number of subjects: 551
Study 34271337 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse Childhood Experiences (ACEs)
Number of subjects: 618
Study 34271337 — intervention group
Group type: EXPERIMENTAL
Intervention: Childhood Caregiving Environment (CCE) scale
Number of subjects: 618
Study 35789430 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 4018
Study 35789430 — intervention group
Group type: COMPARATOR
Intervention: Prasugrel
Number of subjects: 4018
Study 32921130 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental health interventions (not specified)
Number of subjects: 641
Study 32921130 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical health interventions (not specified)
Number of subjects: 641
Study 32921130 — intervention group
Group type: EXPERIMENTAL
Intervention: Access to general practices
Number of subjects: 641
Study 32921130 — intervention group
Group type: COMPARATOR
Intervention: Community rehabilitation, psychosocial interventions, and case management
Number of subjects: 641
Study 32919912 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 1431
Study 32919912 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (control group)
Number of subjects: 1431
Study 32919912 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (baseline PHQ-9 scores)
Number of subjects: 1431
Study 32919912 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (worsening depressive symptoms)
Number of subjects: 1431
Study 34160603 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (health education, systematic auscultation, and opportunistic ECG)
Number of subjects: 2231
Study 34160603 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup A (ECG at each visit)
Number of subjects: 2231
Study 34160603 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup B (ECG only if arrhythmia detected)
Number of subjects: 2231
Study 34160603 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2231
Study 33966607 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth voice messaging intervention
Number of subjects: 0
Study 33966607 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 33518473 — intervention group
Group type: EXPERIMENTAL
Intervention: Otamixaban
Number of subjects: 8656
Study 33518473 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin plus eptifibatide
Number of subjects: 8656
Study 33518473 — intervention group
Group type: EXPERIMENTAL
Intervention: Procedural complications
Number of subjects: 8656
Study 32909702 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser-assisted flapless corticotomy (LAFC)
Number of subjects: 32
Study 32909702 — intervention group
Group type: EXPERIMENTAL
Intervention: Piezocision
Number of subjects: 32
Study 32909702 — intervention group
Group type: COMPARATOR
Intervention: Both LAFC and piezocision
Number of subjects: 32
Study 36256638 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling message addressing user-centered concerns about self-injection (treatment group)
Number of subjects: 24354
Study 36256638 — intervention group
Group type: COMPARATOR
Intervention: No counseling message (control group)
Number of subjects: 24354
Study 33369937 — intervention group
Group type: EXPERIMENTAL
Intervention: NOV03 4 times daily (QID)
Number of subjects: 336